Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

There has been some discussion about the number of

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154837
(Total Views: 763)
Posted On: 06/03/2020 4:26:06 PM
Posted By: CDiddy
There has been some discussion about the number of patients in the Ph2 mild to moderate trial, and whether or not unblinding early would have a significant impact on the statistical probabilities.

I got to thinking, I wonder if the format of the trial and the metrics has any bearing on the statistical strength (p value)

PRIMARY OUTCOME MEASURE
Clinical improvement by change in total symptom score

SECONDARY OUTCOME MEASURES
1. Time to clinical resolution
2. Change from baseline in NEWS2
3. Change from baseline in pulse oxygen saturation
4. Change in baseline in the patients health status on a 7 category scale
5. Incidence of hospitalization
6. Duration of hospitalization
7. Incidence of mechanical ventilation
8. Duration of mechanical ventilation
9. Incidence of oxygen use
10. Duration of oxygen use
11. Mortality rate
12. Time to return to normal activity

OTHER OUTCOME MEASURES:
1. Change in size of lesion area by chest radiograph or CT
2. Change from baseline in serum cytokine occupancy levels
3. Change from baseline in CCR5 receptor occupancy levels
4. Change from baseline in CD3+, CD4+ and CD8+ T cell counts.

In other words, as compared to the severe trial which has a binary outcome (mortality), does the 17 different measurements for each patient help to create more statistical strength which may offset the small patient sample?



(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us